top
Search terms
Results 1 - 3 of 3 - ordered by :
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/09/2015
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015 Item size : 220026 bytes